Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 06:40PM GMT
Release Date Price: $137.24
Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Head of Healthcare Research

Hey, everybody. It's Alethia Young here. I cover large cap, small mid cap biotech here at Cantor. Very happy to have Sarepta Therapeutics. It probably needs no introduction, but I will introduce them anyway. We've got our main man, Doug Ingram, here on the left square if you could see my box, President and CEO; and in the lower square, you've got the man of the hour, Ian Estepan, who's SVP, Chief of Staff and Corporate Affairs. You got to keep the intros lively at this hour, right?

Questions & Answers

Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Head of Healthcare Research

I want to just kind of start off, Doug, your gene therapy really needs no introduction, and we'll obviously we'll get into those in a fair amount. But I think one thing that's important to talk about is the breadth of the pipeline and the platform technologies. So talk about that and then just also talk about some of the upcoming catalysts and milestones over the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot